Caribou Biosciences, Inc. Depreciation and Amortization
Caribou Biosciences, Inc. (CRBU) reported Depreciation and Amortization of $1.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DepreciationDepletionAndAmortization · last filed 2026-08-13
- Caribou Biosciences, Inc. depreciation, depletion and amortization for the quarter ending 2026-06-30 was $625.00K, a 46.44% decline year-over-year.
- Caribou Biosciences, Inc. depreciation, depletion and amortization for the quarter ending 2026-03-31 was $649.00K, a 44.29% decline year-over-year.
- Caribou Biosciences, Inc. depreciation, depletion and amortization for the quarter ending 2025-12-31 was $682.00K, a 42.40% decline year-over-year.
- Caribou Biosciences, Inc. depreciation, depletion and amortization for the quarter ending 2025-09-30 was $631.00K, a 46.39% decline year-over-year.
- Caribou Biosciences, Inc. depreciation, depletion and amortization for fiscal 2025 was $3.65M, a 7.18% decline from fiscal 2024.
- Caribou Biosciences, Inc. depreciation, depletion and amortization for fiscal 2024 was $3.93M, a 11.40% increase from fiscal 2023.
- Caribou Biosciences, Inc. depreciation, depletion and amortization for fiscal 2023 was $3.52M, a 117.32% increase from fiscal 2022.
- Caribou Biosciences, Inc. depreciation, depletion and amortization for fiscal 2022 was $1.62M, a 64.84% increase from fiscal 2021.
| Period end | Depreciation, Depletion and Amortization 3 month | Depreciation, Depletion and Amortization 6 month | Depreciation, Depletion and Amortization 9 month | Depreciation, Depletion and Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $625.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.27M 10-Q · filed 2026-08-13 | $1.96M derived: sum of 3 quarters · filed 2026-08-13 | $2.59M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $649.00K 10-Q · filed 2026-05-07 | $1.33M derived: sum of 2 quarters · filed 2026-05-07 | $1.96M derived: sum of 3 quarters · filed 2026-05-07 | $3.13M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $682.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.31M derived: sum of 2 quarters · filed 2026-03-05 | $2.48M derived: sum of 3 quarters · filed 2026-08-13 | $3.65M 10-K · filed 2026-03-05 |
| 2025-09-30 | $631.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.80M derived: sum of 2 quarters · filed 2026-08-13 | $2.96M 10-Q · filed 2025-11-12 | $4.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.33M 10-Q · filed 2026-08-13 | $3.52M derived: sum of 3 quarters · filed 2026-08-13 | $4.69M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.17M 10-Q · filed 2026-05-07 | $2.35M derived: sum of 2 quarters · filed 2026-05-07 | $3.53M derived: sum of 3 quarters · filed 2026-05-07 | $4.38M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.36M derived: sum of 2 quarters · filed 2026-03-05 | $3.22M derived: sum of 3 quarters · filed 2026-03-05 | $3.93M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.03M derived: sum of 2 quarters · filed 2025-11-12 | $2.74M 10-Q · filed 2025-11-12 | $3.48M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $856.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.57M 10-Q · filed 2025-08-12 | $2.31M derived: sum of 3 quarters · filed 2025-08-12 | $3.88M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $710.00K 10-Q · filed 2025-05-08 | $1.45M derived: sum of 2 quarters · filed 2025-05-08 | $3.03M derived: sum of 3 quarters · filed 2025-05-08 | $3.65M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $740.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $2.32M derived: sum of 2 quarters · filed 2025-03-10 | $2.94M derived: sum of 3 quarters · filed 2025-03-10 | $3.52M 10-K · filed 2025-03-10 |
| 2023-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.20M derived: sum of 2 quarters · filed 2024-11-06 | $2.79M 10-Q · filed 2024-11-06 | $3.29M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $617.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.21M 10-Q · filed 2024-08-06 | $1.71M derived: sum of 3 quarters · filed 2024-08-06 | $2.16M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $589.00K 10-Q · filed 2024-05-07 | $1.09M derived: sum of 2 quarters · filed 2024-05-07 | $1.54M derived: sum of 3 quarters · filed 2024-05-07 | $1.90M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $506.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $956.00K derived: sum of 2 quarters · filed 2024-03-11 | $1.31M derived: sum of 3 quarters · filed 2024-03-11 | $1.62M 10-K · filed 2024-03-11 |
| 2022-09-30 | $450.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $808.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.12M 10-Q · filed 2023-11-07 | $1.39M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $358.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $666.00K 10-Q · filed 2023-08-08 | $939.00K derived: sum of 3 quarters · filed 2023-08-08 | $1.20M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $308.00K 10-Q · filed 2023-05-09 | $581.00K derived: sum of 2 quarters · filed 2023-05-09 | $841.00K derived: sum of 3 quarters · filed 2023-05-09 | $1.07M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $533.00K derived: sum of 2 quarters · filed 2023-03-09 | $763.00K derived: sum of 3 quarters · filed 2023-03-09 | $984.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $260.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $490.00K derived: sum of 2 quarters · filed 2022-11-08 | $711.00K 10-Q · filed 2022-11-08 | $931.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $230.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $451.00K 10-Q · filed 2022-08-09 | $671.00K derived: sum of 3 quarters · filed 2022-08-09 | $897.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $221.00K 10-Q · filed 2022-05-09 | $441.00K derived: sum of 2 quarters · filed 2022-05-09 | $667.00K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $446.00K derived: sum of 2 quarters · filed 2022-03-21 | $900.00K 10-K · filed 2022-03-21 | |
| 2020-09-30 | $226.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $680.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $454.00K 10-Q · filed 2021-09-02 | |||
| 2019-12-31 | $751.00K 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |